Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Other Operating Expenses (2020 - 2023)

Historic Other Operating Expenses for Alaunos Therapeutics (TCRT) over the last 9 years, with Q4 2023 value amounting to $3.7 million.

  • Alaunos Therapeutics' Other Operating Expenses changed N/A to $3.7 million in Q4 2023 from the same period last year, while for Sep 2024 it was $3.7 million, marking a year-over-year increase of 38812.01%. This contributed to the annual value of $4.5 million for FY2023, which is 348721.8% up from last year.
  • According to the latest figures from Q4 2023, Alaunos Therapeutics' Other Operating Expenses is $3.7 million.
  • Alaunos Therapeutics' Other Operating Expenses' 5-year high stood at $20.3 million during Q3 2020, with a 5-year trough of -$15.8 million in Q4 2020.
  • Over the past 4 years, Alaunos Therapeutics' median Other Operating Expenses value was $1.0 million (recorded in 2023), while the average stood at $5.2 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first soared by 10469.39% in 2021, then crashed by 8421.05% in 2023.
  • Over the past 4 years, Alaunos Therapeutics' Other Operating Expenses (Quarter) stood at -$15.8 million in 2020, then surged by 104.69% to $740000.0 in 2021, then plummeted by 117.97% to -$133000.0 in 2022, then surged by 2911.28% to $3.7 million in 2023.
  • Its last three reported values are $3.7 million in Q4 2023, $1.0 million for Q3 2023, and -$245000.0 during Q2 2023.